Cal­i­for­nia stem cell clin­ic to pay out $3.65M set­tle­ment to for­mer pa­tients for in­ef­fec­tive treat­ments

Four years af­ter the FDA ad­mon­ished stem cell clin­ic Stem­Genex for mak­ing du­bi­ous claims about its ser­vices in treat­ing in­cur­able dis­eases, and 3 years af­ter the com­pa­ny first filed for bank­rupt­cy, the clin­ic and its for­mer CMO seem to have reached their fi­nal des­ti­na­tion: a $3.65 mil­lion bill in a class ac­tion set­tle­ment.

Fed­er­al judge An­tho­ny Battaglia in San Diego gave fi­nal ap­proval to the deal in late Feb­ru­ary, with the in­sur­ance car­ri­ers for the now-dead clin­ic along with Stem­Genex’s for­mer CMO and os­teopath An­dre Lal­lande foot­ing the bill and pay­ing 1,063 for­mer clients. The in­sur­ance for the clin­ic will pay $1.15 mil­lion, and the in­sur­er for Lal­lande, a rheuma­tol­o­gist, will pay $2.5 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER